Abstract:
Interdisciplinary tools in drug development have extended the limitations of modern therapeutics. We are now able to address a vast array of diseases with previously unmet needs, however, there persists limitations in the understanding of molecular drivers of diseases, and biology which remains elusive or undruggable. These limitations are highlighted within inflammatory diseases where treatment still focuses on alleviating symptoms. This paradigm leaves 65% of patients non-responsive to current drugs, resulting in up to $85 billion in wasted drug spend every year.
